Observational studyThe Laryngoscope2025
Reduction of Rescue Treatment With Dupilumab for Chronic Rhinosinusitis With Nasal Polyps in Japan.
Observational study in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Connecting the Airways: Current Trends in United Airway Diseases.Journal of personalized medicine · 2026Review
- A Literature Review of the Management of Nasal Polyps: Biologics Combined With Endoscopic Surgery.Cureus · 2025Review
- Reduction of Rescue Treatment With Dupilumab for Chronic Rhinosinusitis With Nasal Polyps in Japan.The Laryngoscope · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveAdd-on dupilumab provides significant symptomatic improvement for individuals with chronic rhinosinusitis with nasal polyps (CRSwNP); however, little is known about the impact of dupilumab in reducing rates of rescue treatment for CRSwNP in Japanese real-world practice settings. This observational study examined the impact of add-on dupilumab treatment on disease burden, including the use of rescue therapy, in Japanese individuals with CRSwNP.
methodsThe study analyzed individual participant data from a Japanese hospital-based administrative claims database between January 1, 2019, and March 31, 2023. Data were collected for each individual from 12 months prior to the index date (the start date of dupilumab administration) to 12 months after the index date (follow-up period). The primary outcome was the change in overall rate of rescue treatment (systemic corticosteroid [SCS] use or endoscopic sinus surgery [ESS]) before and after the initiation of dupilumab.
resultsThe study included 438 individuals with CRSwNP (mean ± SD age of 53.9 ± 13.4 years; 56.6% male). The overall rate of rescue treatment before and after initiation of dupilumab treatment was 7.89 events per patient-year (PY) and 2.14 events per PY, respectively (p < 0.0001), and there was a 73% reduction in the rate of rescue treatment. Compared with the pre-index period, a lower rate of SCS prescriptions (7.54 vs. 2.05) and ESS procedures (0.35 vs. 0.05) during the follow-up was observed, respectively, and there was a 72% reduction in the rate of SCS prescriptions. The mean ± SD daily SCS dose decreased from 7.1 ± 9.7 mg in the pre-index period to 6.1 ± 7.3 mg during follow-up.
conclusionIn this real-world study, add-on dupilumab treatment significantly reduced the requirement for rescue treatment in Japanese individuals with CRSwNP. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.